Why people choose to measure MRD with clonoSEQ:
The most sensitive measure of MRD
currently available1
FDA-cleared & CLIA-validated*
clonoSEQ has nationwide
Medicare coverage†
Alter the course of treatment with
clonoSEQ
What to know about MRD
MRD levels are highly prognostic of outcomes2-6MRD status provides valuable information throughout care2-6MRD testing is recommended by clinical practice guidelines in multiple myeloma, CLL, and ALL7-10
*clonoSEQ MRD test is FDA-cleared for B-ALL, CLL, and MM. clonoSEQ MRD test is CLIA-validated for DLBCL, but has not been cleared or approved by the FDA.
†Medicare Advantage patients may have out-of-pocket costs for their unmet deductible or copays.
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
References
- clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
- Thompson PA, et al. Leukemia. 2018;32(11):2388-2398.
- Martinez-Lopez J, et al. J Hematol Oncol. 2021;14(1):126.
- Friend BD, et al. Pediatr Blood Cancer. 2020;67(2):e28079.
- Al-Sawaf O, et al. J Clin Oncol. 2021;39(36):4049-4060.
- Ching T, et al. BMC Cancer. 2020;20(1):612.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.5.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 1, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.3.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 1, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Acute Lymphoblastic Leukemia V.1.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 1, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 1, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Data on file. Adaptive Biotechnologies. 2021.